Paging Dr. Kardashian?
There is no such thing as bad publicity… unless you have Kim Kardashian West as a spokesperson and the FDA is after you for making misleading claims about your product. Last week, the Food and Drug Administration Office of Prescription Drug Promotion sent a Warning Letter to the Pennsylvania-based pharmaceutical company, Duchesnay, Inc. for failing to include risk information in an Instagram post about her experience with Diclegis, a drug intended to alleviate severe morning sickness in pregnant women. *See screen capture from Instagram here.
The FDA specifically took issue with the omission of limitations on the use of Diclegis and all risk information, noting not only its absence in the post, but the arguable expressly misleading statement by Kardashian that “…it’s been studied and there was no increased risk to the baby.”
The FDA’s Warning Letter requests that Duchesnay immediately cease misbranding the drug and selling it in interstate commerce and gives the company until August 21st to provide an official written response to the Agency.